Dose standardization of botulinum toxin.
Van den Bergh
P Y
PY
Service de Neurologie, Cliniques Universitaires St-Luc, Brussels, Belgium.
Lison
D F
DF
D000818:Animals; D018726:Anti-Dyskinesia Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001764:Blepharospasm / Q000188:drug therapy; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D003680:Deglutition Disorders / Q000139:chemically induced; D004421:Dystonia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007928:Lethal Dose 50; D051379:Mice; D008815:Mice, Inbred Strains; D009128:Muscle Spasticity / Q000188:drug therapy; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects
D018726:Anti-Dyskinesia Agents; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A